Edesa Biotech, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2021. This filing reports annual results; it does not provide standalone fourth-quarter financial results. Edesa is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-related diseases. Its common shares trade on Nasdaq under EDSA.
Financial performance and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $0 | $0.33 million |
| Research and development expense | $17.95 million | $3.33 million |
| General and administrative expense | $5.73 million | $3.38 million |
| Total operating expenses | $23.68 million | $6.73 million |
| Grant and other income | $10.34 million | $0.04 million |
| Net loss | $13.34 million; $1.10 per share | $6.36 million; $0.74 per share |
| Net cash used in operating activities | $13.66 million | $4.99 million |
Revenue ceased as Edesa wound down sales of legacy product inventory. R&D spending rose primarily with EB05 clinical-program milestones and increased trial, investigational-drug, personnel and related costs. G&A increased with compensation, headcount and professional fees. The $10.34 million of grant income largely offset higher expenses, but the annual net loss still more than doubled. Operating margins are not meaningful given no FY 2021 revenue and the company’s development-stage operations.
At September 30, 2021, cash and cash equivalents were $7.84 million, working capital was $10.63 million, total assets were $14.58 million and shareholders’ equity was $13.06 million. Total liabilities were $1.53 million, including $1.38 million in accounts payable and accrued liabilities and $0.10 million in lease liabilities; the filing does not show material funded debt. Accumulated deficit was $26.50 million. Cash from financing activities was $14.17 million, including equity offerings and warrant and option exercises. No significant capital expenditures were reported.
Management said available cash, remaining grant funds and equity-distribution sales were expected to support operations for at least 12 months. This depends on continued access to capital and eligible grant reimbursements. Edesa reported a $3.03 million SIF reimbursement receivable at year-end. Subsequent to year-end, it sold 223,396 shares for approximately $1.29 million gross under a new at-the-market (ATM) program authorizing up to $15 million in gross proceeds.
Business developments and material changes
- EB05: A monoclonal antibody targeting TLR4, under study for COVID-19-associated acute respiratory distress syndrome (ARDS). Phase 2 enrollment and treatment were completed in September 2021; the company reported more than 600 subjects enrolled in the Phase 2/3 study as of December 27, 2021.
- EB01: A topical, non-steroidal sPLA2 inhibitor being evaluated in a Phase 2b study for chronic allergic contact dermatitis (ACD). In June 2021, a DSMB reviewed blinded interim data and found key study parameters had been met; enrollment continued.
- EB02: An exploratory candidate for hemorrhoids disease. The company was evaluating when to initiate the planned study while prioritizing EB05 and EB01.
- EB06: An additional antibody candidate targeting CXCL10; development plans were less advanced.
R&D expense increased by $14.62 million year over year. The company also completed a $10 million gross public offering in March 2021, issued shares through its prior ATM program and exercised warrants and options. The 250 Series A-1 preferred shares issued to obtain a license were converted into common shares during FY 2021. Common shares outstanding increased from 9.62 million at September 30, 2020 to 13.30 million at September 30, 2021, and were 13.52 million as of December 27, 2021.
Clinical outlook, risks and unusual items
- In September 2021, the EB05 DSMB recommended proceeding to a Phase 3 confirmatory trial after identifying what it called a clinically important mortality signal in Phase 2. In critically ill patients receiving ECMO and/or invasive ventilation plus organ support, reported 28-day mortality was 14.3% (2/14) with EB05 plus standard of care versus 36.8% (7/19) with placebo plus standard of care. The reported hazard-ratio analysis had a 95% confidence interval of 0.66–15.35 and p=0.15.
- In a supplemental-oxygen group, reported 28-day mortality was 8.2% (5/61) versus 12.0% (9/75); in the severe-ARDS subgroup it was 16.7% (2/12) versus 42.9% (6/14), with a reported 95% confidence interval of 0.59–14.60 and p=0.19. These small-subgroup, interim findings are not definitive evidence of efficacy; the filing says Phase 3 would focus on critically ill patients. The DSMB reported no meaningful difference in serious or non-serious treatment-emergent adverse events.
- Management was considering expedited regulatory pathways for EB05, but no designation or approval was assured. Clinical benefit, trial completion, regulatory review and commercialization remain uncertain.
- The Canadian Strategic Innovation Fund agreement provides up to C$14.05 million (approximately $11 million) in nonrepayable reimbursement funding for eligible EB05-related work. Edesa reported meeting performance and reporting requirements as of December 27, 2021; the agreement nevertheless includes remedies, including possible funding termination or repayment, for certain breaches.
- Key risks include continuing losses and financing needs; clinical, regulatory and commercialization uncertainty; COVID-19-related enrollment and site disruptions; dependence on third-party manufacturers and CROs amid supply constraints and longer lead times; competition; foreign-exchange exposure; and reliance on in-licensed intellectual property. The company disclosed potential milestone payments of up to $356 million under its NovImmune license, up to $69.1 million under the 2021 inventor license, and up to $18.6 million under the Yissum license, generally contingent on future milestones, as well as royalties or sublicensing payments.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the external auditor did not provide an internal-control attestation because Edesa was a smaller reporting company.
Investor verification priorities
- Review the complete EB05 Phase 2 dataset and subsequent Phase 3 design, enrollment, funding and confirmatory results; distinguish interim subgroup signals from statistically conclusive evidence.
- Confirm remaining SIF funding, eligible expenses, reimbursement timing and compliance with grant obligations.
- Assess cash burn against available cash and working capital, subsequent ATM proceeds, potential dilution and the company’s stated 12-month funding outlook.
- Track EB01 Phase 2b enrollment, completion timing and final results, including effects of pandemic-related disruption.
- Review contractual license milestones, royalty terms, drug-supply commitments and third-party manufacturing capacity as programs advance.